The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer  by Carlson, Josh J. et al.
The Potential Clinical and Economic Outcomes of
Pharmacogenomic Approaches to EGFR-Tyrosine Kinase
Inhibitor Therapy in Non–Small-Cell Lung Cancer
Josh J. Carlson, PhD,1 Louis P. Garrison, PhD,1 Scott D. Ramsey, MD, PhD,1,2 David L. Veenstra, PharmD, PhD1
1Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle,WA, USA;
2Population Health Sciences, Fred Hutchinson Cancer Research Center, Seattle,WA, USA
ABSTRACT
Objectives: Pharmacogenomic applications in oncology offer signiﬁcant
promise, but the clinical and economic implications remain unclear. The
objective of this study was to evaluate the potential cost-utility of imple-
menting epidermal growth factor receptor (EGFR) testing before initiating
second-line therapy for advanced refractory non–small-cell lung cancer
(NSCLC).
Methods: We developed a decision analytic model to evaluate the cost-
utility of EGFR protein expression or gene copy number testing compared
to standard care with erlotinib in refractory advanced NSCLC patients.
Costs and utilities were obtained from publicly available sources. We
performed sensitivity analyses to evaluate uncertainty in the results.
Results: The quality-adjusted life expectancies for erlotinib, EGFR protein
expression testing, and gene copy number testing were: 0.44, 0.48, and
0.50 quality-adjusted life years (QALYs); and the costs were: $57,238,
$63,512, and $66,447, respectively. The most cost-effective testing option,
EGFR gene copy number testing, produced an incremental cost-
effectiveness ratio of $162,018/QALY compared to no testing (erlotinib).
The results were most sensitive to the survival estimates, health state
utilities, and cost of disease progression. In the probabilistic sensitivity
analyses, erlotinib without testing was the optimal treatment strategy until
the $150,000/QALY willingness-to-pay threshold, after which gene copy
testing was optimal. The discounted expected value of perfect information
at a $100,000/QALY threshold in the USA over 5 years was $31.4 million.
Conclusions: The study results suggest that EGFR pharmacogenomic
testing has the potential to improve quality-adjusted life expectancy in the
treatment of refractory NSCLC by a clinically meaningful margin at a
value commensurate with the approved therapies in this setting. Addi-
tional research in this area is warranted.
Keywords: cost-utility, docetaxel, economic evaluation, lung cancer, phar-
macogenetics, erlotinib.
Increased understanding of the molecular mechanisms of cancer
has enhanced our ability to estimate the risk of cancer develop-
ment and relapse [1,2], develop new therapeutics [3–6], and
target therapy according to the unique molecular characteristics
of tumor tissue [7–10]—innovations that generally fall under the
developing ﬁeld of pharmacogenomics. Relative to other disease
areas, a larger number of pharmacogenomic applications in or
near clinical use are available in oncology, including HER2
testing with Herceptin, the OncotypeDx assay in breast cancer,
UGT1A1 testing with irinotecan in colon cancer, and TPMT
testing with 6-mercaptopurine in acute lymphoblastic leukemia,
among others [7–10]. In addition, recent studies have indicated
that pharmacogenomics may play a signiﬁcant role in second-line
non–small-cell lung cancer (NSCLC) treatment with epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
[11–17].
The epidermal growth factor receptor is a cell membrane
protein involved in cellular signaling and the downstream pro-
cesses of apoptosis, cell growth, and cellular differentiation
among others [18]. As such, the EGFR gene is considered a
proto-oncogene or one that could, if altered in its activity or
expression, produce malignancy [19]. It is overexpressed in many
solid tumors including gliomas, breast, colon, and NSCLC,
which led to its candidacy for inhibitor therapy and the devel-
opment of EGFR-targeted agents [18]. The importance of EGFR
in NSCLC is supported by the successful clinical trials for
erlotinib (ERL) (BR.21), which demonstrated better survival
compared to best supportive care (BSC) [3]. Nevertheless, EGFR-
targeted agents have relatively low response rates (~10–20%),
suggesting the potential for a biologically identiﬁable subset of
responder patients [3,20]. In the BR.21 trial, prespeciﬁed sub-
group analyses showed better response and survival for ERL
compared to BSC (hazard ratio [HR] 0.68, 95% CI 0.49–0.95) in
patients who tested positive for high EGFR protein expression
using immunohistochemical (IHC) testing—a method for evalu-
ating the amount of EGFR protein in tumor tissue, whereas no
survival beneﬁt was shown for those testing negative (HR 0.93,
95% CI 0.63–1.36) [12,21]. A similar pattern was found for
patients with high (HR 0.44, 95% CI 0.23–0.82) and low (HR
0.85, 95% CI 0.48–1.51) EGFR gene copy number evaluated
using ﬂuorescent in situ hybridization—a measure of the number
of copies of the EGFR gene in tumor cells [12–17]. These analyses
were retrospective and limited by sample availability with
approximately 33% and 17% of patients able to be evaluated by
IHC and gene copy number testing (GC), respectively [12]. To
date, there have been no clinical trials comparing EGFR testing
versus standard care.
In the absence of direct comparisons in clinical trials, we have
undertaken an indirect comparison to estimate the cost-utility of
EGFR testing in second-line NSCLC using the exploratory data
generated in the BR.21 trial. The objective of this study was to
evaluate the likely clinical and economic impact of implementing
an EGFR testing strategy versus standard care (no testing). This
case is particularly salient as there are a number of drugs devel-
oped or in development targeting EGFR and both gene copy
number and protein expression tests have been proposed as
useful tools for selecting patients for EGFR-TKI therapy
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[13,20,22–25]. Despite the enthusiasm, these clinically available
tests are not commonly used in practice, which is likely attribut-
able to the exploratory nature of the current evidence in favor of
testing. Clearly, more effective interventions in lung cancer treat-
ment are needed because of the high burden of illness (213,000
new cases and 160,000 deaths expected in 2007 in the USA) and
associated economic burden (approximately $5 billion dollars
per year in the USA) [26,27]. The results of this analysis will
inform the ongoing debate and research agenda for EGFR phar-
macogenomic testing in advanced refractory NSCLC.
Research Design and Methods
We developed a decision analytic model using partition survival
methods, in which the overall effectiveness of the interventions
was derived by summing the mean time spent in the progression-
free and disease progression (PD) health states adjusted for
quality of life, to assess the quality-adjusted life years (QALYs)
and associated costs of using a pharmacogenomic testing treat-
ment approach in second-line NSCLC. The model consisted of a
decision tree (Fig. 1) in which patients received ERL mono-
therapy or one of two EGFR testing strategies: EGFR protein
expression test (EGFR PharmDx kit, DakoCytomation, Glos-
trup, Denmark), with ERL given to patients with high expression
(greater than 10% of cells staining) and docetaxel for those with
low expression (IHC); or an EGFR gene copy number test using
ﬂuorescent in-situ hybridization with ERL given to patients with
high copy number according to commonly used criteria and
docetaxel given to those with low copy number [12,17,28]. After
treatment assignment, patients could remain progression-free or
experience PD until death and were followed for time in the
progression-free state, time in PD, quality of life, and costs.
The study population consisted of advanced (stage IIIB/IV)
NSCLC patients 60 years old (approximate median age in the
pivotal trials for the therapies under investigation) who failed at
least one platinum-based chemotherapy regimen and were eli-
gible for treatment with ERL or other chemotherapy in the
second-line setting [3,29,30]. The second-line setting was appro-
priate for comparison because there are three commonly used
therapeutic agents approved by the Food and Drug Administra-
tion for treatment of NSCLC patients who fail to respond or
progress after initial chemotherapy [3,29,30]. Although the
optimal treatment strategy remains uncertain given the lack of
direct comparisons between ERL and either docetaxel or pem-
etrexed, ERL was chosen as the no test comparator because its
efﬁcacy may be inﬂuenced by a patient’s EGFR status. Therefore,
the relevant policy question concerns whether clinicians favoring
the use of ERL should employ an EGFR test before treatment
Figure 1 Decision tree.The schema above illustrates the decision model used in our analysis. Patients entered the model and received an EGFR gene copy number
or protein expression test or standard care with erlotinib.They were followed for time in the progression-free and disease progression health states, adverse events,
and direct medical costs. EGFR, epidermal growth factor receptor; NSCLC, nonsmall cell lung cancer.
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initiation to select an alternative treatment for patients unlikely
to beneﬁt from ERL. In addition, ERL has demonstrated a
similar survival beneﬁt to both docetaxel and pemetrexed
(approximate 2-month survival beneﬁt over BSC) with better
tolerability and ease of administration [31]. We chose docetaxel
for use in test-negatives as it is the most commonly prescribed
chemotherapy agent used in second-line NSCLC and demon-
strated similar survival to pemetrexed in a head to head trial
[29,32]. Patients who fail after second-line treatment were
assumed to receive palliative care until death.
We performed a cost-utility analysis and followed the guid-
ance of the US Panel on Cost-Effectiveness in Health and Medi-
cine [33]. The analysis was conducted from the US societal
perspective with a time horizon of 2 years in the base case (2-year
survival rates in second-line NSCLC: ERL: ~1%, docetaxel: 0%)
[3,29]. Costs and outcomes beyond 1 year were discounted at
3% in the base case [33].
Clinical Inputs
We used estimates of overall survival (OS), from which times in
progression-free survival (PFS) and time in progressive disease
were derived, based on published randomized controlled trials.
Four pivotal trials, comprising the best evidence to date, were
used to evaluate the efﬁcacy of the treatments investigated in this
model [3,29,30,34]. ERL and docetaxel appear to have similar
survival beneﬁts over BSC (approximately 2 months) in unse-
lected advanced refractory NSCLC populations [3,29,30,34]. We
therefore assumed that the OS beneﬁt for docetaxel was equal to
ERL in NSCLC populations of mixed EGFR genomic status—an
assumption used in previous economic evaluations of these treat-
ments [35,36]. Survival estimates for these treatments were based
on the ERL manufacturer’s submission to the National Institute
for Health and Clinical Excellence (NICE) in the UK and a
reanalysis of the BR.21 trial data by Pompen et al. (Table 1)
[35,37].
The survival estimates for the testing arms were calculated as
the average of the survival of the test-positive group (by either
gene copy number or protein expression) which received ERL
and the test-negative group which received docetaxel, weighted
by the estimated prevalence of the testing groups [13,38–40]. We
adjusted our estimates to account for differences between the
subgroup with test results available and the entire study popula-
tion, while maintaining the between genomic group prognostic
relationship (i.e., the relationship between untreated groups) as
well as the within genomic group treatment effect (i.e., the rela-
tionship between the untreated and treated groups within a
genomic subgroup), using the following equations:
OSa OSi TE TE TE where TE OS OSTx Tx all tested Tx BSC+ + += × ×( ) =;
(1)
OSa OSi OS OSBSC BSC allBSC tested BSC− −= × (2)
Where + or - indicates marker positive or negative; all = all study
patients; tested = study patients for whom there are test results;
Tx = treated group; BSC = best supportive care/untreated group;
TE = treatment effect; a = adjusted; and i = unadjusted (e.g.,
OSallBSC = the estimate for the OS in the untreated group from the
entire study population).
Ideally, we would have marker status data for all study par-
ticipants. Nevertheless, using this adjustment, the weighted
average of our survival inputs in the genomic subgroups was
equal to those in the overall study population allowing for com-
parability between our intervention arms.
The treatment beneﬁt of docetaxel was applied to the
adjusted untreated survival estimate from Equation 2 to obtain
the overall treated survival estimate in the test-negative group,
with the assumption that EGFR status does not affect the treat-
ment beneﬁt of docetaxel [41,42]. Times in PFS and PD were
derived by assuming the same ratio of PFS or PD to OS as seen
in the overall study population.
Utilities were derived from two recent community-based
studies in advanced NSCLC from the UK, which used the stan-
dard gamble interview and visual analog scale to assess quality of
life (see Table 1) [43–45]. The disutility for adverse events (AEs)
was applied to the ﬁrst month of therapy as the majority of AEs
occur in ﬁrst month and would not be expected to last longer
than 1 month.
Adverse event rates were estimated from published clinical
trial data and drug package inserts. AEs included were grade 3/4
events greater than 5% or those requiring hospitalization for
either medication. These AEs were chosen as they represent those
likely to impact quality of life and for which direct health-care
costs will accrue.
Resource Utilization and Unit Costs
Drug utilization rates were estimated from the published ran-
domized controlled trials. For ERL, we used mean treatment
duration (4.11 months) and assumed a course of treatment of
150 mg once daily by mouth and adjusted for potential wastage
(5.1%) and dose intensity [35,45,46]. Drug utilization for
patients testing positive was derived by adjusting the treatment
duration in the overall population by the ratio of PFS estimates.
The drug utilization for docetaxel in test-negatives was estimated
using the mean number of cycles from the TAX 317 trial (4.82
cycles) for the 75 mg/m2 group [35–47]. We used the dosing
scale for docetaxel (75 mg/m2) from the key pivotal trials (mean
BSA of 1.8 m2) and adjusted for dose intensity received
[3,10,29,48,49].
For the drugs evaluated, we used the wholesale acquisition
costs for 2006 [31]. The unit costs for medical services were
estimated from the Centers for Medicare & Medicaid Services
(CMS) physicians fee schedule and acute inpatient prospective
payment system [50]. Drug administration costs for docetaxel
included one outpatient ofﬁce visit and 1 hour of intravenous
(IV) infusion time per cycle. Drug administration costs for ERL
included one outpatient ofﬁce visit for the ﬁrst prescription.
Testing costs were estimated using the current procedural
terminology (CPT) codes associated with gene copy number tests
(CPT code: 88368x2) and the PharmDx EGFR protein expres-
sion test (CPT code: 88342) [50]. Additional diagnostics in the
model included routine blood work, chest x-rays, and comput-
erized tomography scans associated with treatment and patient
evaluation.
The cost of febrile neutropenia included hospitalization for
neutropenia (diagnosis-related group [DRG] 398) and one inpa-
tient physician visit. The cost of nonfebrile neutropenia included
one additional outpatient ofﬁce visit. We assumed a proportion
of neutropenic patients received granulocyte colony stimulating
factor for initial treatment and as prophylaxis for subsequent
treatment cycles based on observed rates (docetaxel: 19.2%)
[29,51].
Treatment for severe anemia included one additional outpa-
tient ofﬁce visit. In addition, a proportion of anemic patients
were assumed to receive erythropoietin (one vial per week for 4
weeks) (11.6%) and/or a red blood cell transfusion (10.1%)
based on the observed trial rates [29].
Grade 3/4 rash was assumed to include one outpatient ofﬁce
visit and one tube of Cleocin-T gel [49,52]. Treatment of grade
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3/4 diarrhea included one ofﬁce visit and one bottle of loperam-
ide. Treatment for severe diarrhea included hospitalization (DRG
296) and the costs of inpatient physician visits. Leukopenia was
assumed to be covered by the cost of treating neutropenia
because of the high degree of overlap between conditions. Treat-
ment costs for the remaining AEs included in the model consisted
of one additional outpatient ofﬁce visit per event.
The cost of PD was estimated from two studies which evalu-
ated the cost of care for NSCLC patients in the 6 months before
death using claims analysis data and chart reviews [27,53]. The
average monthly cost was multiplied by the time in PD.
The model included societal costs for patient time based on
an assumed travel distance of 30 miles [54,55]. All costs in the
model were adjusted to 2006 values using the medical compo-
nent of the consumer price index [56].
Assessing Uncertainty
The uncertainty in the model was evaluated using one-way and
multivariate probabilistic sensitivity analysis (PSA). One-way
sensitivity analysis was performed by sequentially varying the
estimates for each model parameter, while keeping the other
Table 1 Model inputs
Base Low High Source
Drug acquisition
Erlotinib 30 day supply (150 mg) $2,894 $2,605 $3,183 [31]
Docetaxel (20 mg vial) $323 $291 $355 [31]
Neupogen (480 mg), 10 vials $3,034 $2,731 $3,337 [31]
Epogen (40,000 units) $487 $438 $536 [31]
Cleocin-T gel (60 g) $70 $63 $77 [31]
Loperamide (2 mg), 30 tablets $4 $4 $4 [31]
Dexamethazone (1 mg) $0.25 $0.23 $0.28 [50]
Medical services
Neutropenic fever requires hospitalization (DRG 398) $6,225 $4,669 $7,781 [31]
Inpatient consultation (CPT code: 99255) $187 $140 $234 [31]
Follow-up consultation (CPT code: 99233) $76 $57 $95 [31]
Outpatient visit (CPT code: 99215) $115 $86 $144 [31]
Hospitalization for diarrhea (DRG 296) $4,218 $3,164 $5,273 [31]
Subcutaneous administration (CPT code: 90722) $18 $14 $23 [31]
Red blood cell transfusion $785 $588 $981 [60]
Chemotherapy infusion, one hour (CPT code: 96413) $166 $124 $207 [50]
EGFR gene copy test (CPT code: 88368 x 2) $320 $240 $400 [50]
EGFR protein expression test (CPT code: 88342) $97 $73 $121 [50]
Complete blood count and blood chemistry proﬁle $44 $33 $55 [61]
Chest x-ray (CPT code: 71030) $47 $35 $59 [62]
CT scan (CPT code: 76355) $418 $313 $522 [63]
Disease progression per month $8,464 $4,811 $12,116 [27,53]
Drug utilization
Duration of epogen treatment (weeks) 4 3 5 [31]
Duration of erlotinib treatment, months 4.11 3.38 4.8 [35]
Dose intensity erlotinib 92% 87% 97% [35]
Wastage (erlotinib) 5.2% 4.9% 5.5% [45]
Docetaxel vials per cycle (20 mg) 1.63 1.22 2.04 [45]
Docetaxel vials per cycle (80 mg) 1.44 1.08 1.80 [45]
Dose intensity docetaxel 94% 89% 99% [29]
Overall survival
Erlotinib alone 9.50 7.82 11.47 [35]
High gene copy number treated with erlotinib 10.63 5.70 20.34 [12]
High protein expression treated with erlotinib 10.47 7.49 14.53 [12]
Low gene copy number treated with docetaxel 11.50 8.84 13.26 [29,35]
Low protein expression treated with docetaxel 10.31 8.24 12.37 [29,35]
BSC BR.21 trial population 7.44 6.60 8.28 [37]
Progression-free survival
Erlotinib alone 4.41 3.63 5.32 [35]
Best supportive care 2.76 2.21 3.31 [35]
Health state utilities
Stable disease on oral therapy 0.67 0.27 0.80 [43]
Stable disease on IV therapy 0.65 0.26 0.78 [43]
Recently progressed disease 0.47 0.19 0.56 [43]
Stable disease plus neutropenia 0.56 0.22 0.67 [43]
Stable disease plus febrile neutropenia 0.56 0.22 0.67 [43]
Stable disease plus diarrhea 0.61 0.24 0.73 [43]
Stable disease plus nausea 0.61 0.24 0.73 [43]
Stable disease plus stomatitis 0.61 0.24 0.73 [43]
Stable disease plus neuropathy 0.62 0.25 0.74 [43]
Stable disease plus rash 0.62 0.25 0.74 [43]
Genomic marker prevalence
Prevalence high EGFR gene copy number 33% 27% 40% [13,38]
Prevalence high EGFR protein expression 50% 40% 60% [39,40]
Range estimates were likely values derived from conﬁdence intervals or reasonable ranges as determined from published sources or expert opinion.
BSC, best supportive care; CPT, current procedural terminology; DRG, diagnosis-related group; EGFR, epidermal growth factor receptor; IV, intravenous.
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parameters constant, within a range of likely values derived from
conﬁdence intervals or reasonable ranges as determined from
published sources or expert opinion (see Table 1). In addition, a
multivariate PSA was performed using second-order Monte
Carlo simulation, in which the model inputs were drawn from
probability distributions (normal distributions for costs, survival
parameters, and utilities and beta distributions for probabilities)
that represent the uncertainty in the estimate. The data were used
to generate a cost-effectiveness acceptability frontier as well as
the expected value of perfect information (EVPI) for the US
population over a 5-year time frame [57]. The EVPI analysis
estimates the average cost (including monetized QALYs) of
wrong decisions because of uncertainty in the model parameters
to estimate the upper bound value of perfect information [58].
Results
The model yielded life expectancies for standard care with ERL,
EGFR protein expression testing (IHC), and EGFR gene copy
number testing (GC) of 0.79, 0.87, and 0.91 years, respectively.
Adjusting for quality of life translated these values into QALY
estimates of 0.44, 0.48, and 0.50, respectively. The cost estimates
were $57,238, $63,512, and $66,447, respectively (Table 2). GC
compared to ERL produced an incremental cost-effectiveness
ratio (ICER) of $162,018/QALY, whereas IHC compared to ERL
produced an ICER of $179,612. IHC was therefore dominated
by extension by GC (i.e., GC is more cost-effective than IHC
versus ERL).
The results of the one-way sensitivity analysis demonstrated
that the effectiveness was most sensitive to uncertainty in the PFS,
OS, and health state utility score on IV therapy estimates. The
cost results were most sensitive to the overall and PFS estimates
and the monthly cost in PD (Fig. 2). The results of the multivari-
ate PSA are provided as a cost-effectiveness frontier (Fig. 3). As
this ﬁgure shows, ERL without testing was the optimal treatment
strategy until the $150,000/QALY threshold, after which gene
copy testing was optimal. The discounted EVPI at the $100,000/
QALY threshold in the USA over 5 years was $31.4 million,
which represents the upper limit value of additional information
at this threshold. Nevertheless, the EVPI varies with willingness
to pay and as there is no agreed upon willingness-to-pay thresh-
old in the USA, the EVPI may be as high as $92 to $100 million,
corresponding with the $50,000 and $150,000/QALY thresh-
olds, respectively (Table 3).
We also undertook a threshold analysis in which we adjusted
the beneﬁt of ERL in the marker-positive groups by extending PFS
and by extensionOS. For the comparison of GC to ERL, we found
that the time in PFS would need to extend from the base case
estimate of 4.93months to 9.24months in high gene copy patients
to achieve and ICER$100,000/QALY. For IHC versus ERL, PFS
would need to extend from 4.86 months in the base case to 7.12
months to achieve the same cost-effectiveness threshold.
Discussion
We evaluated two pharmacogenomic testing strategies for the
treatment of advanced refractory NSCLC patients compared to
standard care with ERL to estimate relative QALYs and treat-
ment costs from the US societal perspective. Our results suggest
there is the potential to improve quality-adjusted life expect-
ancy by 3 weeks at an additional cost of $9200, which yields
an ICER of $162,018/QALY for the comparison of testing
(GC) versus no testing (ERL). The QALY improvement trans-
lates into a 1.4-month survival difference, which is within range
of the treatment beneﬁts observed for ERL and docetaxel over
BSC in the key pivotal trials [3,30]. In addition, the optimal
testing option was found to be GC as it demonstrated better
cost-effectiveness versus standard care with ERL than protein
expression testing. The cost differences were relatively robust to
sensitivity analysis, whereas the QALY differences were sensi-
tive to changes in the efﬁcacy estimates because of the uncer-
tainty in these inputs. The uncertainty in the model is further
reﬂected by the high EVPI, which represents the upper bound
value of perfect information.
Overall, it appears as though pharmacogenomic testing using
the gene copy number test in refractory advanced NSCLC has the
potential to improve quality-adjusted survival over standard care
with ERL by a clinically relevant margin. Although the ICERs are
high, they are reﬂective of the cost of treatment in this setting. In
essence, we would be paying for additional life expectancy at
approximately the same rate we currently pay in this setting as
reﬂected by the comparable cost per month of care for ERL, GC,
and docetaxel ($6025, $6090, and $6330, respectively). If we are
willing to use these treatments alone at their current value, it is
reasonable to assume we would be willing to pay for the added
cost of a pharmacogenomic test to optimize treatment selection
and provide additional beneﬁt.
There are a number of limitations in this analysis that
warrant mention. The most signiﬁcant limitation was the lack of
data on marker status for the overall BR.21 population. The
tested population is different from the overall study population
both in terms of overall composition as well as the relative
balance between the treated and untreated groups owing to the
loss of randomization integrity. This difference is likely to be in
part systematic as those with sufﬁcient tumor tissue available for
genomic analysis are more likely to have had prior surgical
resection of their tumor which may indicate better prognosis at
the time of diagnosis. The impact of this limitation is difﬁcult to
quantify; however, sensitivity ranges for these inputs were based
on observed 95% conﬁdence intervals and the best pharmacoge-
nomic option (GC) maintained a 71% probability of improving
QALYs over ERL in the PSA (data not shown).
Because this study is an indirect comparison, we do not have
information as to the relative clinical efﬁcacy, safety, and resource
utilization for the interventions in the same population. As such,
Table 2 Costs and effects by intervention
Cost results Effectiveness results ICERs
Test costs Drug costs Other costs Total costs LYs QALY PFS QALY PD Total QALYs ($/LY) ($/QALY)
GC $320 $11,553 $54,573 $66,447 0.91 0.27 0.23 0.5
IHC $97 $11,834 $51,581 $63,512 0.87 0.26 0.22 0.48
ERL $0 $11,683 $45,555 $57,238 0.79 0.25 0.2 0.44
GC-ERL $320 -$130 $9,018 $9,209 0.12 0.03 0.03 0.06 $78,367 $162,018
GC, EGFR gene copy number testing; ERL, erlotinib; ICER, incremental cost-effectiveness ratio; IHC, immunohistochemical testing for EGFR protein expression; LY, life-year;
PD, progressive disease; PFS, progression-free survival; QALY, quality-adjusted life year.
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Figure 2 One way sensitivity analysis. BSC, best supportive care;DOC, docetaxel; ERL, erlotinib;GC, gene copy number testing; IHC, protein expression testing;OS,
overall survival; PD, progressive disease; PFS, progression-free survival; QALY, quality-adjusted life year.
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Figure 3 Cost-effectiveness acceptability frontier.
This ﬁgure provides the results of the probabilistic
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we assumed the same treatment beneﬁt in terms of OS (i.e., OS in
treated vs. BSC) for ERL and docetaxel. Although NICE has
expressed some concerns with this assumption, it has face validity
in that a recent ad hoc subgroup analysis comparing patients with
similar levels of prior chemotherapy (less than 2) and performance
status of 0 or 1 reported median survivals for ERL and docetaxel
of 9.4 and 9.1 months, respectively [35–46]. Ultimately, direct
comparative trials are needed to determine whether there are
statistically or clinically signiﬁcant differences in survival and PFS
between the treatment strategies.
Finally, the use of mean survival values derived from the
published time to event survival curves using area under the curve
calculations as opposed to estimates from individual patient level
data is a limitation. Nevertheless, this method compared favor-
ably against the published mean values for the overall treatment
beneﬁt (1.99 months vs. 2.06 months, respectively) [12,35,37].
Ideally, patient-level data from controlled trials would be used.
The results of our analysis are primarily hypothesis generating
because of the reliance on retrospective analyses of data from
randomized controlled trials. In this capacity, they provide a
compelling argument for additional investigations of the clinical
application of EGFR pharmacogenomic testing in advanced
NSCLC.Our results suggest that using EGFRGC to select patients
for treatment in second-lineNSCLC is a promising tool for patient
selection and warrants further high-level investigation, especially
given the high EVPI.
Conclusion
The results of our study suggest that EGFR pharmacogenomic
testing has the potential to improve quality-adjusted life expect-
ancy in the treatment of refractory NSCLC by a clinically mean-
ingful margin at a value commensurate with the approved
therapies available in this setting. Given the high degree of uncer-
tainty as to the relative effectiveness of these treatments,
particularly in the genomic subgroups, the results of ongoing and
future comparative clinical trials will provide valuable insight
into the optimal treatment in second-line NSCLC and the poten-
tial of pharmacogenomic testing therein [59].
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